Navigation Links
Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
Date:12/14/2011

t facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.  Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items.  Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items.  We define non-GAAP diluted loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.  Our definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsoncology.com.

About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Compan
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and ATLANTA , August 28, ... US Food and Drug Administration (FDA) cleared the MagVita TMS ... adult patients who have failed to receive satisfactory improvement from ... non-invasive technique for stimulating neural tissue in the part of ... The procedure has been proven safe and effective and MagVenture ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Asthma Medication Linked to Respiratory Improvement in NYC ... ... corticosteroids (ICS),antiinflammatory treatments often prescribed for asthma, may be beneficial,in preventing ... 2007, the 73rd annual international scientific assembly,of the American College of ...
... 24 Pharmasset, Inc.,(Nasdaq: VRUS ) has ... and,Drug Administration (FDA) for R7128 for the treatment ... a prodrug of PSI-6130, an oral cytidine,nucleoside analog ... Pharmasset,s collaboration with Roche. Pharmasset is currently,enrolling a ...
Cached Medicine Technology:Inhaled Steriods Used as Preventive Treatment Post 9/11 2Inhaled Steriods Used as Preventive Treatment Post 9/11 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 2R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 4R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 5
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... price on Zoom teeth whitening. For just $199, patients can currently receive a one ... traditional in-office teeth whitening procedures, but it includes a number of unique features that ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to ... available for general use any time soon, according to educational website Surviving Mesothelioma. ... that received orphan drug designation for mesothelioma last week from the FDA, will now ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... now consolidated as MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in ... number of custodial files the PSC may receive for corporate employees involved in ...
(Date:8/28/2015)... ... 28, 2015 , ... An independent study recently conducted confirms ... of change to treatment recommendations and diagnosis. The 2015 return on investment (ROI) ... and analyzed WorldCare’s second opinion process. , The study reviewed cases across three ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... , ... poll, Supporting Iraq and Afghanistan Troops and Veterans, found two out of three Americans know ... and Afghanistan veterans and troops face. , ... Washington, DC (Vocus) May 10, 2010 -- A new public awareness poll, ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... ... Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical College ... University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn is ...
... show need for treatment even when pulmonary disease looks ... News) -- Worsening of chronic obstructive pulmonary disease (COPD) ... stroke, a new study finds. , British researchers looked ... in 426 patients and 633 ischemic strokes (blockage of ...
... help University of Central Florida researchers explore new ways ... and other neurological disorders. Stephen Lambert, an associate ... of UCF,s Hybrid Systems Laboratory, has received $428,000, the ... team will study the breakdown of myelin, a substance ...
... dyslexia often struggle with reading, writing, and spelling, despite ... other areas. New neurological research has found that these ... structural differences within an important information highway in the ... The findings are published in the June 2010 issue ...
Cached Medicine News:Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 2Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 3Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3Health News:$1.9 million grant to help UCF find multiple sclerosis 'nerve-ana' 2Health News:Differences in language circuits in the brain linked to dyslexia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: